Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 23.1 EX-23.1
- 23.2 EX-23.2
- 23.3 EX-23.3
- 99.1 EX-99.1
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
Associated filings
- 28 Mar 23 EFFECT Notice of effectiveness
- 24 Mar 23 POS AM Prospectus update (post-effective amendment)
- 7 Jun 21 EFFECT Notice of effectiveness
- 18 May 21 POS AM Prospectus update (post-effective amendment)
- 12 Feb 21 424B3 Prospectus supplement
- 12 Feb 21 EFFECT Notice of effectiveness
-
8 Feb 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 16 Oct 20 S-4 Registration of securities issued in business combination transactions
VYNT similar filings
Filing view
External links
Exhibit 99.8
February 8, 2021
Cancer Genetics, Inc.
201 Route 17 North, 2nd Floor
Rutherford, New Jersey
Consent to Reference in Proxy Statement/Prospectus/Information Statement
Cancer Genetics, Inc. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus/information statement included in such registration statement as a future member of the board of directors of the Company.
Sincerely, | |
/s/ Marcus Boehm | |
Marcus Boehm |